Disparate Outcomes and Treatment Patterns in Polycythemia Vera Across an Integrated Academic-Community Network (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1384; Location: LEVEL 3, HALL B3; "Ruxolitinib or interferon use beyond first-line hydroxyurea was lower in NAC vs CCC patients with high-risk PV (29.5% vs 50%, P < 0.01). Within an integrated cancer network, PV treatment patterns and outcomes differed by care site and provider specialty. Compared with CCC or specialist care, community-managed patients had higher incident TEs and worse survival, calling for collaborations to mitigate disparities."
Acute Myelogenous Leukemia • Chronic Eosinophilic Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
|
|
Jessica Nino de Rivera MD 1; Alifya Lokhandwala MD 1; Angela Tramontano MPH 2; Jessica Freydman PharmD 1; Orly Leiva MD 3; Gabriela Hobbs MD 1; Michelle Lee MD 1
|